Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4 + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 174, Issue 8, 2005, Pages 4525-4534

  Kohm, Adam P ^a   Williams, Julie S ^a   Bickford, Allison L ^a   McMahon, Jeffrey S ^a   Chatenoud, Lucienne ^b   Bach, Jean François ^b   Bluestone, Jeffrey A ^c   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY CD3; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 17044425656     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.8.4525     Document Type: Article

References (51)

1. Kreuwel, H. T., and L. A. Sherman. 2001. The T-cell repertoire available for recognition of self-antigens. Curr. Opin. Immunol. 13:639.
2. Zhang, X., R. Hupperts, and M. De Baets. 2003. Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis. Immunol. Res. 28:61.
3. Karandikar, N. J., C. L. Vanderlugt, J. A. Bluestone, and S. D. Miller. 1998. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J. Neuroimmunol. 89:10.
4. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, and J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84:1374.
5. Hirsch, R., R. E. Gress, D. H. Pluznik, M. Eckhaus, and J. A. Bluestone. 1989. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142:737.
6. Hirsch, R., M. Eckhaus, H. Auchincloss, D. H. Sachs, and J. A. Bluestone. 1988. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140:3766.
7. Hayward, A. R., and M. Shreiber. 1989. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J. Immunol. 143:1555.
8. Chatenoud, L., J. Primo, and J. F. Bach. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158:2947.
9. Belghith, M., J. A. Bluestone, S. Barriot, J. Megret, J. F. Bach, and L. Chatenoud. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9:1202.
10. Chatenoud, L. 2003. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3:123.
11. von Herrath, M. G., B. Coon, T. Wolfe, and L. Chatenoud. 2002. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol. 168:933.
12. Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, and J. A. Bluestone. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692.
13. Masteller, E. L., and J. A. Bluestone. 2002. Immunotherapy of insulin-dependent diabetes mellitus. Curr. Opin. Immunol. 14:652.
14. Alegre, M. L., K. Gastaldello, D. Abramowicz, P. Kinnaert, P. Vereerstraeten, L. De Pauw, P. Vandenabeele, M. Moser, O. Leo, and M. Goldman. 1991. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52:674.
15. Alegre, M., P. Vandenabeele, V. Flamand, M. Moser, O. Leo, D. Abramowicz, J. Urbain, W. Fiers, and M. Goldman. 1990. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur. J. Immunol. 20:707.
16. Ferran, C., K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L. H. Noel, G. Grau, J. Bluestone, and J. F. Bach. 1990. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20:509.
17. Hirsch, R., L. Chatenoud, R. E. Gress, D. H. Sachs, J. F. Bach, and J. A. Bluestone. 1989. Suppression of the humoral response to anti-CD3 monoclonal antibody. Transplantation 47:853.
18. Ramasamy, R., D. S. Secher, and K. Adetugbo. 1975. CH3 domain of IgG as binding site to Fc receptor on mouse lymphocytes. Nature 253:656.
19. Smith, J. A., Q. Tang, and J. A. Bluestone. 1998. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J. Immunol. 160:4841.
20. Alegre, M. L., J. Y. Tso, H. A. Sattar, J. Smith, F. Desalle, M. Cole, and J. A. Bluestone. 1995. An anti-murine CD3 monoclonal antibody with a low affinity for Fcγ receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155:1544.
21. Utset, T. O., J. A. Auger, D. Peace, R. A. Zivin, D. Xu, L. Jolliffe, M. L. Alegre, J. A. Bluestone, and M. R. Clark. 2002. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29:1907.
22. Chatenoud, L., E. Thervet, J. Primo, and J. F. Bach. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91:123.
23. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:75.
24. Vanderlugt, C. L., T. N. Eagar, K. L. Neville, K. M. Nikcevich, J. A. Bluestone, and S. D. Miller. 2000. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 164:670.
25. Kennedy, M. K., R. J. Clatch, M. C. Dal Canto, J. L. Trotter, and S. D. Miller. 1987. Monoclonal antibody-induced inhibition of relapsing EAE in SJL/J mice correlates with inhibition of neuroantigen-specific cell-mediated immune responses. J. Neuroimmunol. 16:345.
26. Tompkins, S. M., J. Padilla, M. C. Dal Canto, J. P. Ting, L. Van Kaer, and S. D. Miller. 2002. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168:4173.
27. Smith, J. A., J. Y. Tso, M. R. Clark, M. S. Cole, and J. A. Bluestone. 1997. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185:1413.
28. Rao, P. E., G. Olini, J. Kille, E. Muchmore, M. A. Talle, G. Brake, and S. A. Rudnick. 1991. OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees. Transplantation 52:691.
29. Waid, T. H., B. A. Lucas, J. S. Thompson, L. C. Munch, S. Brown, R. Kryscio, R. Prebeck, M. A. VanHoy, and D. Jezek. 1991. Treatment of acute rejection with anti-T-cell antigen receptor complex αβ (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial. Transplant. Proc. 23:1062.
30. Waid, T. H., B. A. Lucas, J. S. Thompson, S. Brown, D. Moore, P. Amlot, and G. Janossy. 1989. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody. Transplant. Proc. 21:1778.
31. 2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant. Proc. 23:270.
32. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49:1117.
33. h1 cells that is augmented by IL-4. Int. Immunol. 13:1109.
34. Brown, A., D. E. McFarlin, and C. S. Raine. 1982. Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab Invest. 46:171.
35. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389.
36. Kuchroo, V. K., C. A. Martin, J. M. Greer, S. T. Ju, R. A. Sobel, and M. E. Dorf. 1993. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental autoimmune encephalomyelitis. J. Immunol. 151:4371.
37. Khoury, S. J., W. W. Hancock, and H. L. Weiner. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355.
38. Merrill, J. E., D. H. Kono, J. Clayton, D. G. Ando, D. R. Hinton, and F. M. Hofman. 1992. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc. Natl. Acad. Sci. USA 89:574.
39. 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57.
40. Racke, M. K., A. Bonomo, D. E. Scott, B. Cannella, A. Levine, C. S. Raine, E. M. Shevach, and M. Rocken. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961.
41. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
42. Begolka, W. S., C. L. Vanderlugt, S. M. Rahbe, and S. D. Miller. 1998. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 161:4437.
43. Tang, Q., J. A. Smith, G. L. Szot, P. Zhou, M. L. Alegre, K. J. Henriksen, C. B. Thompson, and J. A. Bluestone. 2003. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J. Immunol. 170:1510.
44. Herold, K. C., J. B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, and J. A. Bluestone. 2003. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J. Clin. Invest. 111:409.
45. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160:1212.
46. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
47. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431.
48. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169:4712.
49. + regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc. Natl. Acad. Sci. USA 99:8213.
50. Furtado, G. C., D. Olivares-Villagomez, M. A. Curotto de Lafaille, A. K. Wensky, J. A. Latkowski, and J. J. Lafaille. 2001. Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol. Rev. 182:122.
51. Chatenoud, L., B. Salomon, and J. A. Bluestone. 2001. Suppressor T cells - they're back and critical for regulation of autoimmunity! Immunol. Rev. 182:149.